Boston Scientific Corporation $BSX Shares Bought by APG Asset Management N.V.

APG Asset Management N.V. lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 5.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,061,037 shares of the medical equipment provider’s stock after buying an additional 57,859 shares during the quarter. APG Asset Management N.V. owned approximately 0.07% of Boston Scientific worth $103,589,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC grew its stake in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the period. World Investment Advisors boosted its holdings in shares of Boston Scientific by 31.7% during the second quarter. World Investment Advisors now owns 16,870 shares of the medical equipment provider’s stock worth $1,812,000 after purchasing an additional 4,061 shares during the last quarter. Keybank National Association OH grew its position in shares of Boston Scientific by 3.1% in the second quarter. Keybank National Association OH now owns 16,219 shares of the medical equipment provider’s stock valued at $1,742,000 after purchasing an additional 493 shares during the period. Assetmark Inc. increased its stake in Boston Scientific by 10.6% in the second quarter. Assetmark Inc. now owns 198,114 shares of the medical equipment provider’s stock valued at $21,279,000 after purchasing an additional 19,026 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. lifted its position in Boston Scientific by 5.6% during the second quarter. Mesirow Financial Investment Management Inc. now owns 3,242 shares of the medical equipment provider’s stock worth $348,000 after buying an additional 172 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Street sentiment and recent analyst commentary lean favorable after the company’s quarterly results and guidance; the board added Cathy Smith and Christophe Weber, which investors view as governance/strategic strengthening. What Does the Street Think About Boston Scientific Corporation (BSX)?
• Positive Sentiment: Boston Scientific arranged multiple credit facilities totaling roughly $11 billion, boosting liquidity and providing financial flexibility for M&A, R&D, or share-repurchase plans — a constructive sign for risk management and capital strategy. Boston Scientific enters into multiple credit facilities totaling $11B
• Positive Sentiment: Management promoted an internal candidate to president of Vascular Therapies, signaling leadership continuity and succession depth in a key growth division. Boston Scientific promotes new president of Vascular Therapies from within
• Neutral Sentiment: Market coverage notes BSX is “trending” and trading up relative to the broader market on the session, driven partly by investor interest after earnings — useful for short-term flows but not a fundamental change. Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note
• Neutral Sentiment: Commentary points out BSX has trailed the Dow over recent periods despite analyst optimism — flags for investors focused on relative performance and timing for rotation into healthcare. Is Boston Scientific Stock Underperforming the Dow?
• Negative Sentiment: FDA-linked reporting: Boston Scientific halted use of certain AXIOS stent delivery devices after deployment issues associated with 167 injuries and three deaths — a material product-safety concern that can affect revenue, litigation exposure and reputation in the short-to-medium term. Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths
• Negative Sentiment: An investor law firm (Pomerantz) has opened an investigation into claims on behalf of BSX investors, increasing legal risk and potential headline volatility. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation – BSX

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. The trade was a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Trading Up 1.2%

NYSE BSX opened at $76.68 on Friday. The firm has a market capitalization of $113.78 billion, a price-to-earnings ratio of 39.52, a PEG ratio of 1.06 and a beta of 0.67. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a one year low of $72.69 and a one year high of $109.50. The company’s 50 day moving average price is $87.31 and its 200 day moving average price is $95.60.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the firm earned $0.70 earnings per share. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on the company. Sanford C. Bernstein restated an “outperform” rating and issued a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. Mizuho decreased their target price on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. BTIG Research restated a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. UBS Group dropped their price target on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Finally, Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $108.36.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.